EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SLPI / FBW7 /c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity

Haofei Chen iD, Xin Li, Weixiong Zhu, Yanxi Mu, Guoqing Zhang, Youheng Zhang, Yusheng Cheng, Wence Zhou iD

Cancer Science · 2026-06 · 117 (6) · 1635-1650

DOI: 10.1111/cas.70369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 01.04.2026. Verfasst von Haofei Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Deoxycytidine, Carcinoma, Pancreatic Ductal, Killer Cells, Natural, Secretory Leukocyte Peptidase Inhibitor. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cuiying Science and Technology Innovation Project of the Second Hospital of Lanzhou University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with dismal prognosis. Although gemcitabine works by directly inducing tumor cell death, as well as activating NK cell‐mediated antitumor immunity, its efficacy remains rather unsatisfying. Currently, biomarkers precisely ascertaining gemcitabine resistance in PDAC are unavailable; thus, it is of much urgency to identify biomarkers accurately predicting gemcitabine sensitivity and explore innovative targets for developing sensitization strategy. Secretory leukocyte protease inhibitor (SLPI) is overexpressed in several solid tumors, but its role in PDAC remains unclear. This study aims to elucidate the function and mechanism of SLPI in modulating gemcitabine sensitivity in PDAC. In this study, we found that SLPI was markedly upregulated in PDAC cell lines and tissues, inversely correlating with gemcitabine efficacy and survival outcome of patients. In vitro, SLPI overexpression significantly reduced PDAC cell sensitivity to gemcitabine‐induced direct cytotoxicity and NK cell‐mediated lysis through enhancing c‐Myc‐driven glycolysis, whereas SLPI knockdown generated the opposite effects. Mechanistically, SLPI could directly interact with c‐Myc protein, which disturbed the binding of E3 ubiquitin ligase FBW7 to c‐Myc and thereby prevented ubiquitination‐mediated c‐Myc degradation, resultantly increasing c‐Myc stability and expression. In vivo, SLPI knockdown substantially sensitized gemcitabine treatment to suppress PDAC growth, and this effect was at least partly dependent on NK cell‐mediated antitumor immunity. Totally, our findings support that SLPI may serve as a promising biomarker for predicting gemcitabine therapy response, and targeting SLPI may be an effective strategy to improve gemcitabine efficacy in PDAC patients. All procedures involving animals were conducted in compliance with institutional ethics regulations and approved by the Ethics Committee of the Second Hospital of Lanzhou University (Approval No. D2025‐434).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineCarcinoma, Pancreatic DuctalKiller Cells, NaturalSecretory Leukocyte Peptidase InhibitorProto-Oncogene Proteins c-mycPancreatic NeoplasmsHumansGemcitabineAnimalsGlycolysisCell Line, TumorDrug Resistance, NeoplasmMiceAntimetabolites, AntineoplasticFemaleXenograft Model Antitumor AssaysF-Box ProteinsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

NK cellsPDACSLPIgemcitabineglycolysis

Substanzen

GemcitabineDeoxycytidineSecretory Leukocyte Peptidase InhibitorProto-Oncogene Proteins c-mycSLPI protein, humanAntimetabolites, AntineoplasticMYC protein, humanF-Box Proteins

Autor:innen und Institutionen

  • The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Gansu Province Hepatobiliary Pancreatic Disease Precision Diagnosis and Treatment Engineering Research Center, Lanzhou University, Lanzhou, China.
  • Gansu Province Key Laboratory of Environmental Oncology, the Second Hospital & Clinical Medical School, Lanzhou University, Lan zhou, China.

ORCID-Profile: Haofei Chen, Wence Zhou

Förderung

  • Cuiying Science and Technology Innovation Project of the Second Hospital of Lanzhou University
  • National Natural Science Foundation of China

Zitieren

APA

Chen, H., Li, X., Zhu, W., Mu, Y., Zhang, G., Zhang, Y., Cheng, Y., & Zhou, W. (2026). SLPI / FBW7 /c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity. Cancer Science, 117(6), 1635-1650. https://doi.org/10.1111/cas.70369

Vancouver

Chen H, Li X, Zhu W, Mu Y, Zhang G, Zhang Y, et al. SLPI / FBW7 /c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity. Cancer Science. 2026;117(6):1635-1650. doi:10.1111/cas.70369

BibTeX
@article{Chen2026,
  author = {Chen, Haofei and Li, Xin and Zhu, Weixiong and Mu, Yanxi and Zhang, Guoqing and Zhang, Youheng and Cheng, Yusheng and Zhou, Wence},
  title = {SLPI / FBW7 /c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {6},
  pages = {1635--1650},
  doi = {10.1111/cas.70369}
}
Kostenlos starten →